A Study to Evaluate the Effect of Hepatic Impairment on JNJ-56136379

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 9, 2020

Primary Completion Date

March 26, 2021

Study Completion Date

March 26, 2021

Conditions

Hepatic Impairment

Interventions

DRUG

JNJ-56136379

JNJ-56136379 will be administered orally in fed condition.

Trial Locations (1)

APEX GmbH, München

All Listed Sponsors

lead

Janssen Sciences Ireland UC

INDUSTRY

NCT04208399 - A Study to Evaluate the Effect of Hepatic Impairment on JNJ-56136379 | Biotech Hunter | Biotech Hunter